ALAlkermes ALKS · NASDAQ
$41.22 +2.79% (+$1.12)
- Market cap
- $6.73B
- Enterprise value
- $7.79B
- P/E
- 101.7x
- Forward P/E
- -
- PEG
- -
- P/S
- 4.0x
- P/FCF
- 30.4x
- EV/EBITDA
- 35.7x
- ROIC
- 2.1%
- Gross margin
- 84.6%
- Net margin
- 4.0%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 4.9x
- Beta
- 0.27
- Free float
- 92.5%
About the company
Alkermes plc is a global biotechnology company focused on the development and manufacturing of innovative medicines for the treatment of neuropsychiatric and oncological diseases. Founded in 1987 and headquartered in Dublin, Ireland, Alkermes specializes in developing drugs for the treatment of mental health disorders such as schizophrenia, depression, and addiction, as well as cancer therapies. The company is known for its technology in the production of long-acting injectable medications, aiming to provide patients with effective and accessible treatment options.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Blair Jackson
Employees
2,050
Headquarters
Dublin
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number